Latest Insider Transactions at Catalent, Inc. (CTLT)
This section provides a real-time view of insider transactions for Catalent, Inc. (CTLT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Catalent, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Catalent, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 25
2022
|
Thomas W Hawkeswood Pres. Pharma Prod Delivery Div |
SELL
Open market or private sale
|
Direct |
671
-9.63%
|
$69,113
$103.04 P/Share
|
|
Aug 25
2022
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Open market or private sale
|
Direct |
1,840
-6.7%
|
$189,520
$103.04 P/Share
|
|
Aug 25
2022
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
SELL
Open market or private sale
|
Direct |
1,670
-7.62%
|
$172,010
$103.04 P/Share
|
|
Aug 25
2022
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
SELL
Open market or private sale
|
Direct |
1,645
-1.86%
|
$169,435
$103.04 P/Share
|
|
Aug 25
2022
|
Mario Gargiulo SVP, Ops, Biologics Europe |
SELL
Open market or private sale
|
Direct |
1,586
-19.97%
|
$163,358
$103.04 P/Share
|
|
Aug 25
2022
|
Steven L Fasman EVP & Chief Admin Officer |
SELL
Open market or private sale
|
Direct |
4,811
-7.22%
|
$495,533
$103.04 P/Share
|
|
Aug 25
2022
|
John R Chiminski Executive Chair |
SELL
Open market or private sale
|
Direct |
38,934
-14.48%
|
$4,010,202
$103.04 P/Share
|
|
Aug 25
2022
|
Thomas P Castellano SVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,414
-6.57%
|
$145,642
$103.04 P/Share
|
|
Aug 25
2022
|
Lorenzo Carletti SVP Global Ops Ph & Cons Hlth |
SELL
Open market or private sale
|
Direct |
1,033
-17.17%
|
$106,399
$103.04 P/Share
|
|
Aug 25
2022
|
Manja Boerman Pres. BioModalities Division |
SELL
Open market or private sale
|
Direct |
3,296
-16.53%
|
$339,488
$103.04 P/Share
|
|
Aug 25
2022
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
SELL
Open market or private sale
|
Direct |
384
-0.68%
|
$39,552
$103.04 P/Share
|
|
Aug 24
2022
|
Kay A Schmidt SVP, Enterprise Functions |
BUY
Grant, award, or other acquisition
|
Direct |
4,139
+18.12%
|
-
|
|
Aug 24
2022
|
Michael A. Riley Pres. Bio Product Delivery Div |
BUY
Grant, award, or other acquisition
|
Direct |
3,973
+27.33%
|
-
|
|
Aug 24
2022
|
Ricardo Pravda Chief Transformation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,117
+19.04%
|
-
|
|
Aug 24
2022
|
Alessandro Maselli President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
10,532
+18.68%
|
-
|
|
Aug 24
2022
|
Patricia Hunt Pres. Consumer Health Div |
BUY
Grant, award, or other acquisition
|
Direct |
949
+8.95%
|
-
|
|
Aug 24
2022
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
BUY
Grant, award, or other acquisition
|
Direct |
3,733
+15.2%
|
-
|
|
Aug 24
2022
|
Thomas W Hawkeswood Pres. Pharma Prod Delivery Div |
BUY
Grant, award, or other acquisition
|
Direct |
1,253
+15.25%
|
-
|
|
Aug 24
2022
|
Scott Gunther SVP, Quality & Reg. Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
5,117
+15.7%
|
-
|
|
Aug 24
2022
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
4,890
+18.24%
|
-
|
|
Aug 24
2022
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
BUY
Grant, award, or other acquisition
|
Direct |
6,771
+7.11%
|
-
|
|
Aug 24
2022
|
Mario Gargiulo SVP, Ops, Biologics Europe |
BUY
Grant, award, or other acquisition
|
Direct |
3,432
+30.18%
|
-
|
|
Aug 24
2022
|
Steven L Fasman EVP & Chief Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,155
+13.22%
|
-
|
|
Aug 24
2022
|
John R Chiminski Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
99,275
+26.97%
|
-
|
|
Aug 24
2022
|
Thomas P Castellano SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,139
+16.14%
|
-
|
|
Aug 24
2022
|
Lorenzo Carletti SVP Global Ops Ph & Cons Hlth |
BUY
Grant, award, or other acquisition
|
Direct |
2,232
+27.05%
|
-
|
|
Aug 24
2022
|
Manja Boerman Pres. BioModalities Division |
BUY
Grant, award, or other acquisition
|
Direct |
6,676
+25.09%
|
-
|
|
Aug 24
2022
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
BUY
Grant, award, or other acquisition
|
Direct |
6,621
+10.52%
|
-
|
|
Jul 27
2022
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
SELL
Open market or private sale
|
Direct |
591
-3.34%
|
$63,237
$107.67 P/Share
|
|
Jul 27
2022
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Open market or private sale
|
Direct |
394
-1.73%
|
$42,158
$107.67 P/Share
|
|
Jul 27
2022
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
SELL
Open market or private sale
|
Direct |
388
-2.23%
|
$41,516
$107.67 P/Share
|
|
Jul 26
2022
|
Kay A Schmidt SVP, Enterprise Functions |
BUY
Grant, award, or other acquisition
|
Direct |
1,115
+7.11%
|
-
|
|
Jul 26
2022
|
Kay A Schmidt SVP, Enterprise Functions |
SELL
Open market or private sale
|
Direct |
323
-2.34%
|
$34,238
$106.9 P/Share
|
|
Jul 26
2022
|
Ricardo Pravda Chief Transformation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,301
+7.25%
|
-
|
|
Jul 26
2022
|
Ricardo Pravda Chief Transformation Officer |
SELL
Open market or private sale
|
Direct |
427
-2.71%
|
$45,262
$106.9 P/Share
|
|
Jul 26
2022
|
Alessandro Maselli President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
10,221
+22.45%
|
-
|
|
Jul 26
2022
|
Alessandro Maselli President & CEO |
SELL
Open market or private sale
|
Direct |
816
-3.15%
|
$86,496
$106.9 P/Share
|
|
Jul 26
2022
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
BUY
Grant, award, or other acquisition
|
Direct |
651
+3.55%
|
-
|
|
Jul 26
2022
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
SELL
Open market or private sale
|
Direct |
312
-1.8%
|
$33,072
$106.9 P/Share
|
|
Jul 26
2022
|
Scott Gunther SVP, Quality & Reg. Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
1,115
+4.67%
|
-
|
|
Jul 26
2022
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Open market or private sale
|
Direct |
450
-2.04%
|
$47,700
$106.9 P/Share
|
|
Jul 26
2022
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
1,301
+6.95%
|
-
|
|
Jul 26
2022
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
SELL
Open market or private sale
|
Direct |
409
-2.48%
|
$43,354
$106.9 P/Share
|
|
Jul 26
2022
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
BUY
Grant, award, or other acquisition
|
Direct |
1,859
+2.23%
|
-
|
|
Jul 26
2022
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
SELL
Open market or private sale
|
Direct |
403
-0.5%
|
$42,718
$106.9 P/Share
|
|
Jul 26
2022
|
Mario Gargiulo SVP, Ops, Biologics Europe |
BUY
Grant, award, or other acquisition
|
Direct |
837
+15.66%
|
-
|
|
Jul 26
2022
|
Mario Gargiulo SVP, Ops, Biologics Europe |
SELL
Open market or private sale
|
Direct |
969
-20.88%
|
$102,714
$106.9 P/Share
|
|
Jul 26
2022
|
Steven L Fasman EVP & Chief Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,788
+4.7%
|
-
|
|
Jul 26
2022
|
Steven L Fasman EVP & Chief Admin Officer |
SELL
Open market or private sale
|
Direct |
2,546
-4.52%
|
$269,876
$106.9 P/Share
|
|
Jul 26
2022
|
John R Chiminski Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
37,165
+17.98%
|
-
|